UNSPSC 51373475: Hydrocodone/phenyltoloxamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373475 Hydrocodone/phenyltoloxamine is a Commodity code that covers pharmaceutical products — specifically opioid-based analgesics and combination formulations — procured by state and local health agencies, counties, and cooperative purchasing alliances to support community health programs, emergency response, and public-health initiatives. State and local governments use this code to acquire controlled pharmaceuticals for distribution through authorized health facilities, harm-reduction programs, and emergency medical services. The issuing-body mix includes county health departments and state-led cooperative purchasing organizations that aggregate demand across multiple jurisdictions and health systems.

Recent activity shows two distinct procurement patterns. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted RFP S1070000015802 in January 2026 to establish multi-award contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local facilities in Minnesota and Oregon; proposals were due March 26, 2026, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and the remainder on administrative compliance, EDI capability, and fee structure. Both solicitations require FDA compliance, cGMP certification where applicable, Drug Supply Chain Security Act adherence, and contractual relationships with authorized wholesalers. Activity concentrates in the Upper Midwest and Southeast, with cooperative purchasing vehicles dominating the volume.